Status:
COMPLETED
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
Lead Sponsor:
Rush University Medical Center
Collaborating Sponsors:
Novo Nordisk A/S
Conditions:
Diabetic Ketoacidosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful...
Eligibility Criteria
Inclusion
- age 18 or older
- venous pH \< 7.3 or arterial \< 7.35
- at least 2 of the following 3:
- serum HCO3 \< 18/anion gap \> 16
- serum glucose \> 300 mg/dl
- serum acetone positive
Exclusion
- pregnant
- less than age 18
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00920725
Start Date
January 1 2005
End Date
December 1 2007
Last Update
August 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612